Search

Paltusotine

Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth

Hydroxyproline

Therapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds. … Hydroxyproline is mostly used as a diagnostic marker of bone turnover and liver fibrosis.

Clopenthixol

Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

Heterotheca inuloides flower

Heterotheca inuloides flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

Meningococcal polysaccharide vaccine group C

It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.

Soybean oil

Derived from soybeans, soybean oil is a common vegetable oil and a source of polyunsaturated and saturated fatty acids. … It is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use.

Dextropropoxyphene

Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. … The levo-isomer appears to exhibit a very limited antitussive effect.

Magnesium acetate

Equine Botulinum Neurotoxin F Immune FAB2

Equine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F.

Digoxin

[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240]